Türkiye is the 19th largest pharmaceutical market in the world. As of January 2025, only 3% of medicines approved by the European Medicines Agency between 2020 and 2023 were available to Turkish patients. Germany: 90%. EU average: 46%.
These two facts belong to the same market. Understanding why they coexist is the starting point for any credible analysis of the life sciences sector in Türkiye, and the only way to identify where the real opportunity sits.
A Pharmaceutical Market Larger Than Most European Companies Realise
The Turkish pharmaceutical market reached TRY 376 billion in 2024, equivalent to USD 11.5 billion at the period’s reference rate. IQVIA classifies Türkiye among the world’s 22 highest-growth emerging pharmaceutical markets.
The growth figure, however, requires reading carefully. Year-on-year expansion in local currency reached 54.5%. In US dollars, it was 11.9%. In units, it was negative: volume fell 3.5% to 2.8 billion units. Around 90% of lira-denominated growth came from administered price increases, not from rising demand. This is not organic market expansion. It is a market catching up with lira depreciation through regulated price revisions.
For a European company modelling commercial potential, the lira growth figure is not the right input. The USD figure, and more importantly the volume trend, tells a more honest story.
The Structural Force That Controls Everything
Türkiye does not operate a pharmaceutical market in the conventional commercial sense. It operates a state-administered procurement system with a market attached to it. The SGK, the public health insurance scheme, covers 93.5% of audited pharmaceutical market value. Prices are set by TİTCK, the Turkish Medicines and Medical Devices Agency, through a fixed reference exchange rate applied to a basket of five southern European countries: France, Italy, Spain, Portugal, and Greece.
This mechanism, known as the “pharma euro,” has consistently lagged the real lira rate. The current 2026 rate stands at TRY 25.3346, following a 16.9% revision published in the Official Gazette in December 2025. A March 2026 presidential decree introduced “value-based pricing” into the regulatory framework. Experts at Gün + Partners, one of Türkiye’s leading life sciences law firms, note that these changes alone are unlikely to significantly improve patient access to innovative therapies without a parallel increase in public pharmaceutical spending. The structural constraint is not being dismantled. It is being incrementally adjusted.
The consequence for an importing company remains unchanged: every molecule priced in euros is translated into lira at a rate that systematically destroys margin. The risk compounds further. If Türkiye is included in a company’s international reference pricing basket, the Turkish price pulls down reimbursement levels in higher-value EU markets. A company launching in Türkiye at TİTCK-administered prices may reduce its French or German reimbursement price as a direct consequence. This is the mechanism that explains why sophisticated multinational pharmaceutical groups, with the resources to navigate complex regulatory environments, elect not to launch in Türkiye. It is not an oversight. It is a calculated decision.
The commercial pathway adds a further layer of friction. Marketing authorisation, pricing approval, SGK reimbursement listing, and sales permit are four sequential administrative processes, each with its own timeline. A company that completes the authorisation stage in twelve months may wait an additional twelve to twenty-four months before holding a sales permit. A product can be legally approved and commercially inaccessible simultaneously.
What the 3% Access Rate Means at Segment Level
The EFPIA Patients W.A.I.T. Indicator 2024 tracked 173 medicines approved by the EMA between 2020 and 2023. Six were available to Turkish patients as of January 2025. That is 3%.
The distribution within this figure is not uniform. Oncology accounts for 68% of patent-protected pharmaceutical sales in Türkiye, reflecting the SGK’s relative willingness to reimburse high-cost cancer treatments compared to other therapeutic areas. Oncology is the one disease area where innovative products reach patients at meaningful scale.
Rare diseases sit at the other extreme. Of 66 orphan drugs receiving EMA approval between 2020 and 2023, only one received SGK reimbursement by 2024. The Named Patient Programme provides a partial workaround: unlicensed drugs can be supplied to identified patients through the Turkish Pharmacists’ Association. For companies with orphan designations, this route can generate early revenue and clinical experience before any formal reimbursement decision is pursued.
Biosimilars occupy a structurally different position. They reduce cost to the SGK system and align with the government’s localisation agenda. The biosimilar segment reached TRY 7.2 billion in 2024, growing at 46% year-on-year against a backdrop of overall unit volume decline. For European companies with biosimilar pipelines, Türkiye is a fundamentally different market than the innovation access figures suggest.
The Manufacturing Base European Companies Consistently Underestimate
The depth of Türkiye’s pharmaceutical manufacturing infrastructure is the most consistently overlooked feature of this sector.
Türkiye hosts 109 pharmaceutical production facilities and 13 active pharmaceutical ingredient plants. The sector employs approximately 50,000 people directly. Domestic production accounts for 90% of unit volumes and 57% of the value of pharmaceuticals sold in-country. Turkish manufacturers export to 186 countries, with USD 2.3 billion in pharmaceutical exports recorded in 2024.
Several Turkish manufacturers hold EU GMP certification and operate to international production standards. Among those with confirmed EU GMP status: Abdi Ibrahim, whose AbdiBio facility carries monoclonal antibody manufacturing capacity following a 2023 technology transfer from Argentine biosimilar producer mAbxience; Koçak Farma, with seven dedicated facilities spanning conventional, oncology, hormone, carbapenem, biotechnology, and API production lines; Santa Farma, which obtained its fourth EU GMP certificate in 2023; Nobel İlaç, whose new biotechnology and injectable plant in Düzce came online in 2024; and Pharmactive, an active contract manufacturer for several major international pharmaceutical groups.
This manufacturing base is not a curiosity. It is the strategic logic for partnership-first market entry in this sector.
The Turkish government’s HIT-30 programme commits USD 30 billion in incentives through 2030, with biotechnological pharmaceuticals named as a priority vertical. Pharmaceutical production qualifies for the second-highest incentive tier regardless of geographic location within the country: tax reductions up to 60%, direct grants covering 30 to 40% of investment, and financing support up to 70%. The window is open, and it is finite.
Biotechnology: Where the Gap Creates the Opportunity
The biotechnology segment reached USD 1.9 billion in 2024, representing 17% of total pharmaceutical value. The EU5 average is 34%. The gap is significant. It also defines the growth opportunity for well-positioned entrants.
161 biotechnology products are currently marketed in Türkiye: 134 reference biologics and 27 biosimilars. Local biosimilar production generated TRY 1.5 billion in 2024, covering only a fraction of domestic biosimilar consumption. The import gap is structural, and it creates direct demand for manufacturing partnerships.
Two recent transactions illustrate the entry models with the strongest risk-adjusted economics. The mAbxience-Abdi Ibrahim technology transfer created a Turkish production base for biosimilar monoclonal antibodies targeting both domestic and regional export markets, bypassing the pricing constraints that make direct distribution unviable. The Alvotech-Polifarma licensing agreement transferred commercialisation responsibility for several biosimilar products to Polifarma, which carries local manufacturing and distribution responsibilities. Both structures reach the Turkish market without exposing the originator company to direct SGK reimbursement negotiations or pharma-euro pricing risk.
TİTCK’s biosimilar regulatory framework follows EMA comparability methodology, requiring at least three lots of the reference biologic for analytical studies. For companies already holding EMA biosimilar approval, the Turkish pathway is demanding but navigable, with industry estimates suggesting an eight to twelve-month timeline for well-prepared applications.
Clinical Research: The Entry Vector European Sponsors Underuse
Türkiye’s position in global clinical research is consistently underrepresented in European market intelligence. In 2024, 172 industry-sponsored clinical trials were initiated, placing Türkiye 20th globally. Of those, 116 were Phase III. Oncology accounts for 39% of new trials, reflecting both the therapeutic area’s commercial importance and the depth of Turkish oncology site infrastructure.
Per-patient trial costs in Türkiye are widely cited at 30 to 50% below EU5 averages, driven by lower site operational costs, investigator fees, and administrative overhead. For a sponsor running a 300-patient oncology study, this differential is not marginal.
The regulatory structure for clinical research offers specific advantages. TİTCK’s authorisation pathway runs in parallel with ethics committee review, with combined timelines commonly cited at four to six weeks for standard applications. Foreign sponsors are not required to submit a local Investigational Medicinal Product Dossier, a meaningful compliance reduction compared to EU Clinical Trials Regulation requirements. The clinical dossier can be submitted primarily in English.
The international CRO presence is established. IQVIA and Syneos Health operate the largest local staffing bases. Monitor CRO and Novagenix provide domestic execution capacity at Phase II and III level. For oncology-focused sponsors in particular, the combination of site experience and patient recruitment infrastructure, including populations with limited prior biologic exposure, represents a genuine operational advantage.
The CRO vector does not require a commercial market entry decision. It is an operational outsourcing decision, and one that builds regulatory relationships and in-country clinical data that strengthen every commercial conversation that follows.
Three Entry Vectors That Work
European life sciences companies that approach Türkiye expecting a direct distribution market will not find one. The 3% innovative medicine access rate resolves any ambiguity on that point. The opportunity sits elsewhere, distributed across three distinct vectors.
Manufacturing and CDMO partnerships. Turkish manufacturers with EU GMP certification represent a regional production base with cost structures, incentive access, and geographic positioning that few European alternatives match. For a European biotech or pharma company seeking to serve MENA, CIS, and domestic Turkish demand from a single location, the partnership economics are compelling without requiring navigation of Turkish pricing or reimbursement policy.
Licensing and commercialization partnerships. For companies seeking Turkish market presence without the operational complexity of a direct subsidiary, the licensing model transfers SGK navigation to a local partner with established relationships and distribution infrastructure. Margin compression is real at the product level. At the portfolio and overhead level, the model can generate sustainable returns without the cost base of direct entry.
Clinical research. The CRO vector is an operational outsourcing decision, not a market entry commitment. It offers 30 to 50% cost reduction per patient, faster site activation than most EU member states, and a regulatory pathway that does not require replicating the full EU compliance architecture. It also generates regulatory standing and clinical data in-country that supports every commercial option that follows.
The Strategic Conclusion
The Turkish life sciences sector in 2026 presents a structural paradox: large market, extensive manufacturing capacity, EU-aligned regulatory framework, and near-zero access to innovative medicines. The paradox resolves the moment the pharma-euro pricing mechanism is understood.
The fixed pharma-euro regime is not a transitional policy waiting to be liberalised. It is a deliberate architecture that prioritises SGK cost containment over commercial returns for innovative product suppliers. It will not change on a two or three-year horizon.
Türkiye rewards those who enter through the factory or the laboratory, not those who enter through the warehouse. The HIT-30 incentive window runs through 2030. The biosimilar manufacturing gap remains wide. The clinical research infrastructure is under-utilised relative to the cost opportunity. These vectors are open now.
We work with European companies navigating entry into the Turkish market and with Turkish companies building toward European expansion. If you are evaluating your options in life sciences, reach out to Wukong Consulting.
FAQ
What is the size of the life sciences market in Türkiye?
The Turkish pharmaceutical market reached TRY 376 billion in 2024, equivalent to USD 11.5 billion, ranking Türkiye 19th globally. The biotechnology segment accounts for USD 1.9 billion, or 17% of total pharmaceutical value, compared to a 34% average across the EU5.
Why are so few European medicines available to Turkish patients?
Türkiye sets pharmaceutical prices through a fixed reference exchange rate applied to a basket of southern European countries. This mechanism, the pharma euro, consistently prices imported innovative medicines below viable commercial margins. As of January 2025, only 3% of medicines approved by the EMA between 2020 and 2023 were available to Turkish patients, the lowest rate of any country surveyed by EFPIA.
Is Türkiye a viable location for clinical research?
Yes. Türkiye initiated 172 industry-sponsored clinical trials in 2024, ranking 20th globally. Per-patient costs are widely cited at 30 to 50% below EU5 averages. The regulatory pathway for foreign sponsors is streamlined compared to EU requirements, with no local Investigational Medicinal Product Dossier required and a clinical dossier accepted primarily in English.
What is the best market entry strategy for a European life sciences company entering Türkiye?
Direct distribution of innovative products is rarely viable given the pricing mechanism. The three entry approaches with the strongest risk-adjusted economics are manufacturing or CDMO partnerships with EU GMP-certified Turkish producers, licensing agreements that transfer SGK navigation to a local commercial partner, and clinical research partnerships that generate in-country data and regulatory relationships without requiring a commercial market entry decision.
Which Turkish pharmaceutical manufacturers hold EU GMP certification?
Several Turkish manufacturers hold confirmed EU GMP status, including Abdi Ibrahim (AbdiBio facility for biologics), Koçak Farma, Santa Farma, Nobel İlaç, and Pharmactive. This base supports CDMO and technology transfer arrangements for European companies seeking regional manufacturing capacity.